Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Hum Immunol ; 65(4): 359-65, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15120191

ABSTRACT

We studied the association of human leukocyte antigen (HLA)-DRB1 and HLA-DQB1 alleles and HLA haplotypes with juvenile rheumatoid arthritis (JRA) in 65 patients and 65 controls from Colombia. The JRA subsets were distinguished on the basis of criteria established by the American College of Rheumatology. Two alleles were associated with protection, HLA-DRB1*1501 (p = 0.002) and HLA-DRB1*1402 (p = 0.01). HLA-DRB1*1602 (p = 0.0000002) was associated with susceptibility for systemic JRA and HLA-DRB1*1104 (p = 0.0002) for pauciarticular JRA. Amino acid sequences at residues 70-74 of DRB1 chain shared by HLA-DRB1 alleles (shared epitomes) were also informative. The polyarticular JRA subset revealed association with (70)QRRAA(74), which includes HLA-DRB1*04, 01, and (70)DRRAA(74), which includes DRB1*1601, 1602, 1101, and 1104. Two new findings of interest were the association of the haplotypes DRB1*1104, DQB1*0301(p = 0.0002) with pauciarticular JRA and DRB1*1602, DQB1*0301 (p = 0.0000002) association with systemic JRA. The DRB1 alleles of these two haplotypes share the epitope (70)DRRAA(74)and were associated with both the pauciarticular and the systemic subset of JRA. Our results suggest that studies of disease susceptibility in populations of admixed genetic background should take into account the contribution of different ethnic groups or nationalities in the recruitment of controls and patients studied in order to rule out genetic stratification.


Subject(s)
Alleles , Arthritis, Juvenile/genetics , HLA-DR Antigens/genetics , Adolescent , Arthritis, Juvenile/diagnosis , Arthritis, Juvenile/etiology , Child , Child, Preschool , Colombia/ethnology , Epitopes/genetics , Ethnicity/genetics , Female , Genetic Markers , HLA-DQ Antigens/genetics , HLA-DQ beta-Chains , HLA-DRB1 Chains , Haplotypes/genetics , Humans , Male , Sequence Analysis, Protein
2.
Biomedica ; 23(3): 254-62, 2003 Sep.
Article in Spanish | MEDLINE | ID: mdl-14582328

ABSTRACT

Oligotypes of the human leukocyte antigen HLA Class II, DRB1 alleles were characterized at the molecular level in a group of Colombian children suffering juvenile rheumatoid arthritis (JRA). The distribution of these alleles was examined in a group of Colombian mestizo children (genetic admixture of Amerindians, Europeans and Africans) suffering from clinically distinct JRA subsets in order to detect HLA allele frequency differences in patients with different JRA subsets. A group of 65 patients with JRA and 65 controls were characterized for the subtypes of the HLA-DRB1 alleles using polymerase chain reaction with sequence-specific oligonucleotide probes (PCR-SSOP). The oligotyping protocol recommended by the 12th International Histocompatibility Workshop held in St. Malo, Paris, in 1996, was used. Subtype HLA-DRB1*1104 was the allele most strongly associated with susceptibility to JRA (Fisher's p = 0.013, odds ratio (OR) = 16.79, etiologic fraction (EF) = 0.93). HLA-DRB1*1602 was also associated with susceptibility to a lesser degree (Fisher's p = 0.016, OR = 8.98, EF = 0.88). HLA-DRB1 alleles participating in JRA protection were HLA-DRB1*1501 (preventive fraction (PF) = 0.466, p = 0.005) and HLA DRB1*1402 (PF = 0.49, p = 0.009). The relationship between some HLA-DRB1 alleles and clinical features was also compared. The presence of rheumatic factor was associated with the alleles HLA-DRB1*0407 (p = 0.05, OR = 11.2, EF = 0.45) and HLA-DRB1*1302 (p = 0.02, OR = 22.8, EF = 0.63). There was also an association between HLA-DRB1*0701 (p = 0.001, OR = 58, EF = 0.73) with expressing ANA +. We found that in the oligoarticular subset, the allele HLA-DRB1*1104 (p = 0.0034, OR = 41.53, EF = 0.97) was the one expressed most commonly. In the poliarticular group, the alleles most frequently expressed were HLA-DRB1*0404 (Fisher's p = 0.012, OR = 8.75, EF = 0.88). In patients with systemic JRA, the HLA-DRB1*1602 allele (p = 0.005, OR = 21.33, EF = 0.95) was most frequent. These results suggested that the MHC genes of mestizo children influence not only the clinical expression of the disease, but also the susceptibility to its development.


Subject(s)
Alleles , Arthritis, Juvenile/genetics , HLA-DR Antigens/genetics , Polymorphism, Genetic , Adolescent , Case-Control Studies , Child , Child, Preschool , Colombia , Female , HLA-DRB1 Chains , Humans , Indians, South American , Male
3.
Biomédica (Bogotá) ; 23(3): 254-262, sept. 2003. tab
Article in Spanish | LILACS | ID: lil-356775

ABSTRACT

Se buscó tipificar molecularmente los alelos de los antígenos de leucocitos humanos HLADRB1 en un grupo de niños mestizos colombianos (población resultante de la mezcla genética de amerindios, europeos y africanos) con artritis reumatoidea juvenil (ARJ), así como analizar su frecuencia de expresión y compararla con sujetos clínicamente normales e investigar la asociación entre la frecuencia de los alelos con los diferentes subgrupos clínicos de ARJ. El estudio involucró 65 pacientes con ARJ y 65 controles sanos. La tipificación de los alelos HLADRB1 se realizó por medio de la metodología de la reacción en cadena de la polimerasa con sondas de oligonucleótidos de secuencias específicas (PCR-SSOP), utilizando el protocolo recomendado por el XII International Histocompatibilty Workshop, realizado en St. Malo, París, en 1996. Los alelos HLADRB1* 1104 (prueba exacta de Fisher, PEF)0,013, OR16,79, frecuencia etiológica (FE)0,93) y DRB1*1602 (PEF0,016, OR8,98, FE0,88) se evidenciaron como marcadores de susceptibilidad. HLA-DRB1*1501 (FP0,466; p0,005) y HLA DRB1*1402 (FP0,49; p0,009) se comportaron como alelos asociados con protección. Al comparar las asociaciones entre alelos y los diferentes subgrupos clínicos se encontró asociación entre ARJ oligoarticular con HLA-DRB1* 1104 ( p0,0034, OR41,53 , FE0,97), la ARJ poliarticular se asoció con el alelo HLADRB1* 0404 ( p0,012, OR8,75, FE0,88 ) y en el grupo sistémico, el alelo más expresado fue el HLA-DRB1*1602 ( p0,005, OR21,33, FE0,95). La presencia de factor reumatoide estuvo asociado con los alelos HLA-DRB1*0407 ( p0,05, OR11,2, FE0,45) y HLA-DRB1*1302 ( p0,02, OR22,8, FE0,63). En el grupo de pacientes con ANA+, sólo hubo significancia estadística para el alelo HLA-DRB1* 0701 ( p0,001, OR58, FE0,73). Nuestros resultados sugieren que los genes del MHC en este subgrupo étnico inciden no sólo en la susceptibilidad a desarrollar ARJ sino también en la expresión clínica de la enfermedad.


Subject(s)
Child , Alleles , Arthritis, Juvenile , Polymorphism, Genetic , HLA-DR1 Antigen/analysis , Colombia
4.
Acta méd. colomb ; 18(3): 157-63, mayo-jun. 1993. tab
Article in Spanish | LILACS | ID: lil-183296

ABSTRACT

Con el objeto de conocer el comportamiento clínico de los diferentes tipos de glomerulopatía lúpica en nuestro medio se hizo un análisis retrospectivo de las historias clínicas de 64 pacientes con diagnóstico clínico e histológico seguidos en el servicio de reumatología del HUSVP de Medellin. Para evaluar la experiencia local con el uso de CFM en la forma de pulsos se seleccionaron 20 pacientes con un mínimo de nueve pulsos y se hizo análisis de los parámetros de función renal, antes de la terapia y al final del período de seguimiento; se hizo además un diseño retrospectivo de casos y controles en el cual estos pacientes fueron comparados con 20 pacientes seguidos antes de 1986 (sin pulsos de CFM). Los resultados muestran predominio de las formas proliferativas (63.1 por ciento) con un comportamiento agresivo. En el grupo tratado con pulsos de CFM, hubo mejoría a estabilización de las pruebas de función renal. Se observó una disminución de la incidencia de IRCT (30 por ciento vs 5 por ciento) y retardo en su presentación.


Subject(s)
Humans , Cyclophosphamide/administration & dosage , Cyclophosphamide/adverse effects , Cyclophosphamide , Glomerulonephritis, IGA , Lupus Coagulation Inhibitor/adverse effects , Kidney Diseases/classification , Kidney Diseases/complications , Kidney Diseases/therapy , Lupus Erythematosus, Systemic/complications
SELECTION OF CITATIONS
SEARCH DETAIL